Binnopharm Group has launched a new pharmaceutical form on the hemostatic market
03.11.2023
In October, Binnopharm Group launched production of tranexamic acid in tablet form, expanding the line of modern generics in the growing segment of hemostatic drugs. Since the beginning of 2023, the hemostatics market volume has amounted to more than RUB 2 billion, showing a year-on-year growth rate of 37 % (according to AlphaRM data). The company's portfolio already includes the drug in the form of a solution for hospital use.
Tranexamic acid in tablets is produced at the company's own facility − ALIUM. The drug is indicated for adults and children over 3 years old for short-term treatment of various types of bleeding and will be available for retail sale in two dosages – 250 mg and 500 mg.
Ekaterina Slavgorodskaya, Sales and Promotion Director of Binnopharm Group: «We are constantly working on development of our portfolio, expanding it not only with new products, but also with new consumer-friendly forms. We are also always modernizing and expanding the capacity of our plants to meet the growing demand of the Russian market for quality drugs».
Tranexamic acid in tablets is produced at the company's own facility − ALIUM. The drug is indicated for adults and children over 3 years old for short-term treatment of various types of bleeding and will be available for retail sale in two dosages – 250 mg and 500 mg.
Ekaterina Slavgorodskaya, Sales and Promotion Director of Binnopharm Group: «We are constantly working on development of our portfolio, expanding it not only with new products, but also with new consumer-friendly forms. We are also always modernizing and expanding the capacity of our plants to meet the growing demand of the Russian market for quality drugs».
